
Opinion|Videos|February 15, 2024
Toxicity Considerations in HR+ Breast Cancer Treatment
Virginia Kaklamani, MD, offers clinical insights on treatment toxicity considerations in HR+ breast cancer, and the Oncology Brothers outline key takeaways from the discussion.
Advertisement
Advertisement
Related to this article

Model data suggest anthracycline-based chemotherapy may cost breast cancer survivors a median of 9.4 life-years through biological age acceleration.

The FDA set a June 25, 2027, PDUFA date for gedatolisib in PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer after endocrine therapy.

Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
Advertisement
Advertisement
Trending on CancerNetwork
1
Matching Neoadjuvant Therapy to Tumor Genomics in High-Risk Prostate Cancer
2
Partnering With Local Hospitals to Manage CRS and ICANS From Bispecific Antibodies
3
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
4
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
5

